From: Prediction model for EBV infection following HLA haploidentical matched hematopoietic stem cell transplantation
Risk group
score
Derivation cohort
Validation cohort
All patients
low
0–3
21/183 (11.5%)
30/163 (18.4%)
51/347 (14.7%)
intermediate
5–6
17/53 (32.1%)
11/48 (22.9%)
28/101 (27.7%)
high
8–11
10/13 (76.9%)
6/6 (100%)
16/19 (84.2%)